Our Portfolio

Abata Therapeutics

Approach: Advancing a novel treatment modality for T1D enabling next-generation immune therapies

Strategic Area: Immunotherapies

T1D Funding Impact: Supporting discovery and development work for T1D alongside strong life sciences investor syndicate

Egle Therapeutics

Approach: Engineered and targeted cytokines to treat autoimmune diseases

Strategic Area: Immunotherapies

T1D Funding Impact: Bringing T1D focus and experience to a multi-indication drug

AnTolRx, Inc.

Approach: Developing antigen-specific immune tolerance therapies for autoimmune and allergic diseases

Strategic Area: Immunotherapies

T1D Funding Impact: Catalyzing company formation and T1D program, together with a pharmaceutical company partner

Bigfoot Biomedical

Approach: Developing a comprehensive diabetes management ecosystem to reduce the burden of diabetes for insulin-dependent individuals living with T1D and T2D

Strategic Area: Improving Lives

T1D Funding Impact: Accelerating the development of interoperable automated insulin delivery systems for people with T1D

Biolinq

Approach: Developing a wirelessly-enabled biosensor patch capable of continuously monitoring multiple biomarkers. Initially focused on a minimally-invasive continuous glucose monitor (CGM) for people with diabetes

Strategic Area: Improving Lives

T1D Funding Impact: Accelerating the development of a clinical-stage next gen sensing platform

Capillary Biomedical

Approach: Clinical-stage novel extended wear insulin infusion set technology to improve the lives of people with T1D on insulin pump therapy

Strategic Area: Improving Lives

T1D Funding Impact: Supporting the development and entry to the clinic of a novel long wear infusion set system for clinical benefit and comfort

Code Biotherapeutics

Approach: Developing a targeted regenerative agent to restore functional beta cell mass

Strategic Area: Beta Cell Therapies

T1D Funding Impact: Bringing T1D focus and experience to a multi-indication platform company

Diasome Pharmaceuticals

Approach: Developing a clinical stage liver-targeted insulin for improved glycemic control

Strategic Area: Improving Lives

T1D Funding Impact: Catalyzing financing alongside VC lead to complete critical clinical studies

DiogenX

Approach: Developing a regenerative agent to restore functional beta cell mass

Strategic Area: Beta Cell Therapies

T1D Funding Impact: Supporting a T1D-focused company founded on compelling science with transformational potential

eGenesis Bio

Approach: Creating a renewable islet source from animal organs

Strategic Area: Beta Cell Therapies

T1D Funding Impact: Bringing T1D experience to a platform company

Enthera

Approach: Developing antibodies that inhibit beta cell death

Strategic Area: Beta Cell Therapies

T1D Funding Impact: Bringing T1D focus and experience to a multi-indication drug

GluSense Medical

Approach: Developing a long-term implantable continuous glucose monitor (CGM) for diabetes patients

Strategic Area: Improving Lives

T1D Funding Impact: Funding to critical value inflection points

GentiBio

Approach: Advancing a novel treatment modality for T1D enabling next-generation immune therapies

Strategic Area: Immunotherapies

T1D Funding Impact: Supporting T1D-focused company to advance a promising immunotherapy work alongside strong life sciences investor syndicate

i2o Therapeutics

Approach: Developing a platform of ionic liquids to enable oral drug delivery of insulin and other therapies

Strategic Area: Improving Lives

T1D Funding Impact: Accelerate the development of a delivery platform enabling oral insulin dosing for more physiologic glucose control

ImmusanT

Approach: Developing a peptide desensitization therapy for T1D

Strategic Area: Immunotherapies

T1D Funding Impact: Catalyzing the creation of a T1D-focused program using a powerful platform

Immunocore

Approach: Soluble TCR bi-specific approach for safer, durable, tissue-specific immunomodulation to preserve beta cells

Strategic Area: Immunotherapies

T1D Funding Impact: Catalyzing the acceleration of a T1D-focused autoimmune program using a powerful platform

IM Therapeutics

Approach: Precision medicine platform developing small molecules blockers of autoimmunity

Strategic Area: Immunotherapies

T1D Funding Impact: Advancing second generation of genetically targeted blockers

Inversago Pharma

Approach: Developing an oral drug to promote beta cell functional recovery

Strategic Area: Beta Cell Therapies

T1D Funding Impact: Bringing T1D focus and experience to a multi-indication drug

Kriya Therapeutics

Approach: Using gene therapy to achieve insulin independence in established T1D

Strategic Area: Beta Cell Therapies

T1D Funding Impact: Bringing T1D expertise to a next-generation gene therapy platform company focused on prevalent and severe chronic diseases

Pandion Therapeutics

Approach: Islet-targeted immunotherapies for safer, durable treatments

Strategic Area: Immunotherapies

T1D Funding Impact: Catalyzing the creation of a T1D-focused program using a powerful platform (TO BE ACQUIRED BY MERCK IN 2021)

Protomer Technologies

Approach: Developing a highly-sensitive glucose-responsive insulin

Strategic Area: Improving Lives

T1D Funding Impact: Accelerating the development of a novel insulin formulation

Provention Bio

Approach: Building and advancing a diversified portfolio of advanced clinical-stage and pre commercial-stage candidates that intercept, prevent or delay the progression of debilitating, life-impacting, and life-threatening diseases such as type 1 diabetes, celiac disease, and lupus (NASDAQ: PRVB)

Strategic Area: Immunotherapies

T1D Funding Impact: Facilitated the acquisition and clinical development of T1D-relevant assets (IPO JULY 2018)

Repertoire Immune Medicines

Approach: Decoding the targets of disease-causing T cells to develop immunotherapy treatments

Strategic Area: Immunotherapies

T1D Funding Impact: Catalyzing the creation of a T1D program using a powerful discovery platform

Semma Therapeutics

Approach: Combining proprietary cells with state-of-the-art devices towards insulin independence

Strategic Area: Beta Cell Therapies

T1D Funding Impact: Funding development of beta cell replacement therapy with JDRF collaboration (ACQUIRED BY VERTEX SEPT. 2019)

Seraxis

Approach: Developing a cell replacement therapy for insulin-dependent diabetes towards a functional cure

Strategic Area: Beta Cell Therapies

T1D Funding Impact: Supporting a T1D-focused company to advance a promising beta cell replacement therapy alongside strategic and financial investors

Sonoma Biotherapeutics

Approach: Developing a promising immune modulator to preserve beta cell function

Strategic Area: Immunotherapies

T1D Funding Impact: Accelerating the development of targeted therapy for T1D

SQZ Biotech

Approach: Creating an off-the shelf cell therapy to retrain the immune system

Strategic Area: Immunotherapies

T1D Funding Impact: Catalyzing the creation of a T1D-focused program and a new tolerance effort on a compelling platform

TetraGenetics

Approach: Engineering a first-in-class, disease modifying immune therapy to prevent beta cell destruction

Strategic Area: Immunotherapies

T1D Funding Impact: Aiding in securing a downstream strategic partner for asset development

Veralox Therapeutics

Approach: Developing a therapeutic to inhibit beta cell stress

Strategic Area: Beta Cell Therapies

T1D Funding Impact: Accelerating the development of early stage therapy for T1D, catalyzing matching participation from other investors